Systemic Lupus Erythematosus

A groundbreaking phase 1 study using CAR-T cells to treat severe lupus highlights a collaborative effort between the Cellular Therapy Program and rheumatology programs to pioneer innovative patient care.

The Xist ribonucleoprotein (RNP) complex, linked to the XX sex chromosome complement, influences the susceptibility to autoimmunity.

The percentage of lymphocyte apoptosis in peripheral blood was significantly higher in patients with jSLE when compared with healthy controls.

A retrospective cohort analysis suggests the monoclonal antibody may help patients with SLE reduce their reliance on oral corticosteroids over 1 year after initiating treatment.

Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials.

In this research presented at ACR 2023, a connection between antiphospholipid antibodies and a greater potential risk of cardiovascular disease was identified.

A lower proportion of patients in the belimumab treatment group experienced ≥1 kidney flare compared with placebo in the overall population.

Patients with SLE who reported being more satisfied in their lives were more likely to have higher physical and mental component summary scores.

The risk of ischemia heart disease was significantly higher in the SLE cohort when compared with controls, with risks peaking between the 6th and 9th year post-diagnosis.

An analysis of data from the APPLE study provides insight into the heterogeneity that exists within pediatric systemic lupus erythematosus patients.

Therapies including biologics and corticosteroids were more frequently used among patients with rheumatoid arthritis and lupus who developed severe COVID-19.

An analysis of more than 250 pregnancies among women with SLE from the Hopkins Lupus Cohort provides insight into risk of adverse pregnancy outcomes based on serum 25-hydroxy vitamin D levels using real-world data.

Pooled data from the phase 3 TULIP program offer additional insight into the effects of anifrolumab use in people with moderate-to-severe systemic lupus erythematosus.

Compared with those without SLE, those with SLE had a higher risk of fetal morbidity and mothers were almost 4 times as likely to require a blood transfusion or develop a cerebrovascular disorder.

Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus erythematosus.

Multivariable models indicated that improvements in the physical component score and mental component score could be predicted by better self-efficacy scores in patients with systemic lupus erythematosus.

The 2-phase study analyzed the association of plasma vitamin D levels with clinical phenotype, serology, and disease variables in a large cohort of patients with systemic lupus erythematosus living in India.

Anxiety and depression can limit engagement with healthcare or treatment leading to later diagnosis, poor treatment adherence, and poor disease control with associated negative sequelae.

Hydroxychloroquine dosing higher than 6 mg/kg was associated with a 15-year risk of nearly 22%, while retinopathy risk with shorter duration of use was significantly lower.

Self-evidence can help rheumatic autoimmune disease patients gain control of symptoms when the standard of care fails them.

Dall'Era notes that it is important for rheumatologists to understand that the current endpoints for SLE clinical trials, such as SRI-4 and BICLA, are complex and imperfect. 

Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.

A significantly larger portion of patients in the telitacicept 160 mg achieved SR14 response compared to the placebo group.

"Infections are one of the key determinants of early morbidity and mortality of patients with SLE, strongly linked to disease activity and immunosuppression."

Preventing chronic damage accrual is one of the top treatment targets, as it is linked to increased mortality and decreased quality of life.